3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
4
Recruiting
2
Unknown
1
Terminated
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
44
Liver Neoplasms
4
Cholangiocarcinoma
3
Advanced Biliary Tract Cancer
3
Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Biliary Tract Neoplasms
2
Thyroid Neoplasms
1
Thyroid Cancer Metastatic
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Recurrence
1
Potentially Resectable Locally Advanced Malignant Tumors of Biliary System
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Liver Cirrhosis
1
Klatskin Tumor
1
Hepatoblastoma
1
HER2-negative Advanced Gastric Cancer
1
Gastric Cancer Metastatic to Liver
1
Gallbladder Neoplasms
1
First-line Treatment
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Tumor
1
Biliary Tract Neoplasms Immunotherapy
1
Advanced Primary Liver Cancer
1
Interventions
Cyclophosphamide
17
fludarabine
13
Dexamethasone
12
Cisplatin
11
Rituximab
10
Gemcitabine
9
Paclitaxel
7
Lenalidomide
7
Decitabine
7
Cytarabine
7
Bendamustine Hydrochloride
7
fludarabine phosphate
6
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
6
Etoposide
6
Carboplatin
6
Bortezomib
6
Radiotherapy
5
Injections
5
Azacitidine
5
camrelizumab
4
apatinib
4
Valproic Acid
4
Thalidomide
4
Procarbazine
4
Oxaliplatin
4
Drug Therapy
4
Antilymphocyte Serum
4
tislelizumab
3
pomalidomide
3
liposomal doxorubicin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Recurrence
×
lenvatinib
×
Clear all
NCT05910970
2024-01-23
PREVENT-2
Guangxi Medical University
Phase 3
Unknown
200 enrolled